Cagrilintide 10mg

Cagrilintide is a long-acting analog of amylin — a pancreatic peptide hormone co-secreted with insulin from beta cells in response to meals — and the most clinically advanced amylin receptor agonist ever developed. While Pramlintide (Symlin) is the only approved amylin analog (for type 1 and type 2 diabetes), its short half-life requires 2–3 daily injections. Cagrilintide is engineered with fatty acid conjugation and structural modifications that extend its half-life to enable once-weekly dosing — matching the dosing convenience of semaglutide and making it practical for long-term obesity and metabolic management.

Amylin and GLP-1 are mechanistically complementary yet distinct in their pathways. GLP-1 primarily reduces food intake by activating hypothalamic GLP-1 receptors to increase satiety signaling and reduce appetite, while also slowing gastric emptying. Amylin reduces food intake through the area postrema (AP) and nucleus tractus solitarius (NTS) in the brainstem — different neuroanatomical circuits that converge on appetite suppression but through separate receptor populations. This complementarity is why the combination of cagrilintide with semaglutide (the CagriSema combination being developed by Novo Nordisk) produces weight loss greater than either alone: two independent satiety pathways are simultaneously activated.

The amylin receptor signaling pathway involves a heterodimeric receptor complex consisting of the calcitonin receptor (CTR) combined with receptor activity-modifying proteins (RAMPs 1, 2, or 3). This receptor complex activates cAMP and MAPK signaling cascades in amylin-responsive neurons. Beyond appetite suppression, amylin receptor signaling has multiple metabolic effects: suppression of glucagon secretion after meals (reducing post-meal hepatic glucose output), slowing gastric emptying (reducing the rate of glucose absorption and blunting postprandial glucose spikes), and through central effects, influencing energy expenditure and body weight set-point regulation.

CagriSema Phase 3 trial data (REDEFINE-1) published in 2024 showed 22.7% mean weight loss at 68 weeks — the highest weight reduction ever recorded in a Phase 3 obesity trial for any pharmaceutical, surpassing tirzepatide's 22.5% (SURMOUNT-1) and semaglutide's 14.9% (STEP-1). This establishes CagriSema as the new efficacy benchmark for obesity pharmacotherapy, and places cagrilintide's contribution — the approximately 8% additional weight loss it adds when combined with semaglutide — as one of the most clinically significant recent additions to the metabolic pharmacology armamentarium.

The 10mg vial provides extended supply for ongoing weekly dosing protocols. Clinical dose escalation for cagrilintide follows a similar titration schedule as GLP-1 agonists: starting at 0.25–0.5mg weekly and escalating to the target 2.4mg dose over 16 weeks to minimize GI adverse effects.